Overview
Transverse Abdominus Plane Block Study
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2024-02-12
2024-02-12
Target enrollment:
0
0
Participant gender:
All
All
Summary
Study the effect of laparoscopic guided TAP block on opioid consumption and associated costs using a mixture of dexmedetomidine, dexamethasone, and ropivacaine versus Liposomal bupivacaine (Exparel®) in patients who undergo elective minimally invasive colorectal surgery.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
University of Colorado, DenverTreatments:
BB 1101
Bupivacaine
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Dexmedetomidine
Ropivacaine
Criteria
Inclusion Criteria:- provision to sign and date the consent form.
- stated willingness to comply with all study procedures and be available for the
duration of the study.
- Male and female patients aged 18 and older
- Benign or malignant colorectal disease undergoing laparoscopic, robotic, or a "hybrid"
(minimally invasive dissection with a 6-8 cm incision to complete the surgery)
colorectal resection with or without an ostomy
Exclusion Criteria:
- Pregnant or breastfeeding patients
- Medical conditions that may interfere with the use of the study medications (e.g.,
drug allergy),
- Patients with opioid dependence defined as chronic opioid use more than 3 times per
week preoperatively
- Incarcerated individuals
- Age less than 18 years-old
- Urgent/emergent operations as defined by need for operation within 24 hours
- Other conditions or general disability or infirmity that in the opinion of the
investigator precludes further participation in the study.
- Enrollment in another concurrent study with use of investigational drugs